The intersection of TB and HIV infection is increasing the global burden of both diseases. HIV infection greatly increases the risk of TB converting from latent to active infection, and TB infection increases morbidity and mortality in the HIV+ population. In 2006, the HU CFAR sponsored a national meeting on TBHIV coinfection, which led to the creation of a working group of HU CFAR members focused onTB-HlV research, and identification of a major unmet need: a BSL-3 biocontainment facility that would allow for cell sorting and imaging. When new facilities for the Ragon Institute were being constructed, the HU CFAR Membership successfully petitioned the Phillip T and Susan M Ragon Foundation to include a state of the art BSL-3 laboratory to meet these needs. These recently completed facilities include 2240 square feet of BSL- 3 level space, flow cytometry and cell sorting, animal handling, imaging and additional space to accommodate temporary equipment. With HU CFAR support this facility is now home of a newly created HU CFAR BSL-3 Core. Dr. Daniel Kavanagh serves as the PI, working closely with Dr Sarah Fortune, an internationally recognized expert in studies of TB who serves as Director of the newly-created Ragon TB Program, with close interactions with the HU CFAR TB-HIV Scientific Working Group. Drs. Fortune and Kavanagh jointly supervise a team of fellows, staff scientists, and a facility manager who bring extensive experience in safe and productive of BSL-3-level research. The combined talents of this team, as well as state-of-the-art BSL-3 facilities, are, available to the HU CFAR community. HU CFAR users are offered training and certification to conduct experiments within the facility;alternatively Core staff are available to carry out standard tissue culture and microbiology procedures on behalf of researchers who do not wish to work inside the facility. The proposed HU CFAR Biosafety Level 3 Core is guided by the following specific aims: 1. Provide training and consultation for members of HU CFAR community members who are planning TB related projects 2. Provide access to BSL-3 microbiology, tissue culture, live cell microscopy, live FACS, animal facilities, and special projects.

Public Health Relevance

Considered independently, the HIV and TB epidemics represent two of the greatest global health challenges of our time. As such, the HU CFAR leadership has placed HIV-TB research as a top priority area for research. The proposed BSL-3 Core will address several areas of significance including insights into pathogenesis, international engagements, biocontainment needs, and fostering of research synergies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI060354-11
Application #
8697515
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
11
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Harvard Medical School
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02138
Mayer, Kenneth H; Chan, Philip A; R Patel, Rupa et al. (2018) Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States. J Acquir Immune Defic Syndr 77:119-127
Kirtane, Ameya R; Abouzid, Omar; Minahan, Daniel et al. (2018) Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. Nat Commun 9:2
Richterman, Aaron; Cheung, Hoi Ching; Meiselbach, Mark K et al. (2018) Risk Factors for Self-Reported Cholera Within HIV-Affected Households in Rural Haiti. Open Forum Infect Dis 5:ofy127
Calabrese, Sarah K; Earnshaw, Valerie A; Krakower, Douglas S et al. (2018) A Closer Look at Racism and Heterosexism in Medical Students' Clinical Decision-Making Related to HIV Pre-Exposure Prophylaxis (PrEP): Implications for PrEP Education. AIDS Behav 22:1122-1138
Luong Nguyen, Liem B; Yazdanpanah, Yazdan; Maman, David et al. (2018) Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness. Clin Infect Dis 67:719-726
Lodi, Sara; G√ľnthard, Huldrych F; Dunn, David et al. (2018) Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. AIDS 32:327-335
Howe, Chanelle J; Dulin-Keita, Akilah; Cole, Stephen R et al. (2018) Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. Am J Epidemiol 187:316-325
Gholizadeh, Shadi; Rooney, Benjamin M; Merz, Erin L et al. (2018) Body Image and Condomless Anal Sex Among Sexual Minority Men Living with HIV. AIDS Behav 22:658-662
North, Crystal M; Allen, Joseph G; Okello, Samson et al. (2018) HIV Infection, Pulmonary Tuberculosis, and COPD in Rural Uganda: A Cross-Sectional Study. Lung 196:49-57
Andersen, Lena S; Magidson, Jessica F; O'Cleirigh, Conall et al. (2018) A pilot study of a nurse-delivered cognitive behavioral therapy intervention (Ziphamandla) for adherence and depression in HIV in South Africa. J Health Psychol 23:776-787

Showing the most recent 10 out of 1030 publications